| Developing cohort | Validation cohort | ||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
T stage | Â | 0.003 | Â | 0.011 |
 T2 vs. T1 | 1.091 (0.853–1.396) | 0.488 | 1.566 (1.142–2.145) | 0.005 |
 T3 vs. T1 | 1.533 (1.159–2.028) | 0.003 | 1.631 (1.136–2.342) | 0.008 |
N stage |  | < 0.001 |  | < 0.001 |
 N1 vs. N0 | 4.699 (3.593–6.146) | < 0.001 | 3.515(2.533–4.878) | < 0.001 |
 N2 vs. N0 | 7.478 (5.576–10.03) | < 0.001 | 5.789 (4.022–8.332) | < 0.001 |
TNM stage |  | < 0.001 |  | < 0.001 |
 TNM II vs. TNM I | 3.822 (2.879–5.072) | < 0.001 | 3.315 (2.304–4.767) | < 0.001 |
 TNM III vs. TNM I | 7.234 (5.310–9.856) | < 0.001 | 6.158 (4.131–9.179) | < 0.001 |
Grade, G3/4 vs. G1/2 | 1.551 (1.227–1.960) | < 0.001 | 2.220 (1.683–2.929) | < 0.001 |
PNI, with vs. without | 0.648 (0.413–1.017) | 0.059 | 1.834 (1.084–3.103) | 0.024 |
LVI, with vs. without | 1.693 (1.289–2.223) | < 0.001 | 1.836 (1.320–2.555) | < 0.001 |
Ki67, ≥ 40% vs. <40% | 1.327(1.085–1.622) | 0.006 | 1.266(0.972–1.647) | 0.080 |
G-Ki67 |  | < 0.001 |  | < 0.001 |
 II vs. I | 1.308 (1.047–1.633) | 0.018 | 1.316 (0.973–1.780) | 0.075 |
 III vs. I | 1.821 (1.386–2.391) | < 0.001 | 2.688 (1.889–3.826) | < 0.001 |
R status, R1 vs. R0 | 1.050 (0.830–1.329) | 0.684 | 1.381 (1.074–1.774) | 0.012 |
Adjuvant therapy, with vs. without | 1.675 (1.520–1.845) | < 0.001 | 1.505 (1.318–1.718) | < 0.001 |